TG Therapeutics (CH:NKB2)
NASDAQ:NKB2
Total Valuation
TG Therapeutics has a market cap or net worth of CHF6.58B. The enterprise value is $8.20B.
Market CapCHF6.58B
Enterprise Value$8.20B
Share Statistics
TG Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders7.54%
Owned by Institutions12.56%
Financial Efficiency
TG Therapeutics’s return on equity (ROE) is 0.69 and return on invested capital (ROIC) is 13.54%.
Return on Equity (ROE)0.69
Return on Assets (ROA)0.42
Return on Invested Capital (ROIC)13.54%
Return on Capital Employed (ROCE)0.14
Revenue Per Employee1.75M
Profits Per Employee1.27M
Employee Count352
Asset Turnover0.58
Inventory Turnover0.80
Valuation Ratios
The current PE Ratio of TG Therapeutics is 16.6. TG Therapeutics’s PEG ratio is 0.00523.
PE Ratio16.6
PS Ratio6.98
PB Ratio6.64
Price to Fair Value6.64
Price to FCF-172.18
Price to Operating Cash Flow-551.00
PEG Ratio0.00523
Income Statement
In the last 12 months, TG Therapeutics had revenue of 616.29M and earned 447.18M in profits. Earnings per share was 3.10.
Revenue616.29M
Gross Profit515.57M
Operating Income123.32M
Pretax Income107.39M
Net Income447.18M
EBITDA134.36M
Earnings Per Share (EPS)3.10
Cash Flow
In the last 12 months, operating cash flow was -13.95M and capital expenditures -240.00K, giving a free cash flow of -14.19M billion.
Operating Cash Flow-13.95M
Free Cash Flow-14.19M
Free Cash Flow per Share-10.00T>
Dividends & Yields
TG Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
TG Therapeutics upcoming earnings date is Aug 10, 2026, TBA (Confirmed).
Last Earnings DateMay 6, 2026
Next Earnings DateAug 10, 2026
Ex-Dividend Date―
Financial Position
TG Therapeutics as a current ratio of 4.10, with Debt / Equity ratio of 129.23%
Current Ratio4.10
Quick Ratio3.29
Debt to Market Cap0.06
Net Debt to EBITDA1.35
Interest Coverage Ratio4.61
Taxes
In the past 12 months, TG Therapeutics has paid -339.79M in taxes.
Income Tax-339.79M
Effective Tax Rate-3.16
Enterprise Valuation
TG Therapeutics EV to EBITDA ratio is 33.37, with an EV/FCF ratio of -179.45.
EV to Sales7.28
EV to EBITDA33.37
EV to Free Cash Flow-179.45
EV to Operating Cash Flow-181.00
Balance Sheet
TG Therapeutics has CHF514.43M in cash and marketable securities with CHF753.56M in debt, giving a net cash position of -CHF239.13M billion.
Cash & Marketable SecuritiesCHF514.43M
Total DebtCHF753.56M
Net Cash-CHF239.13M
Net Cash Per Share-CHF10.00T>
Tangible Book Value Per ShareCHF4.49
Margins
Gross margin is 83.04%, with operating margin of 20.01%, and net profit margin of 72.56%.
Gross Margin83.04%
Operating Margin20.01%
Pretax Margin17.43%
Net Profit Margin72.56%
EBITDA Margin21.80%
EBIT Margin21.76%
Analyst Forecast
The average price target for TG Therapeutics is CHF37.60, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF37.60
Price Target Upside― Downside
Analyst ConsensusModerate Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast―